
Alembic Pharmaceuticals Limited has informed the Exchange about press release dated 14-Nov-2022 titled Alembic Pharmaceuticals receives USFDA Final Approval for Cyclophosphamide Capsules, 25 mg and 50 mg.
Filed with NSE ·

Alembic Pharmaceuticals Limited has informed the Exchange about press release dated 14-Nov-2022 titled Alembic Pharmaceuticals receives USFDA Final Approval for Cyclophosphamide Capsules, 25 mg and 50 mg.
6ix hasn’t read this filing yet.
Alembic Pharmaceuticals Limited on 6ix
Follow Alembic Pharmaceuticals into a list and get an email when it puts out news.
Follow Alembic Pharmaceuticals